NCT07720167 Albumin-Bound Paclitaxel Non-small cell lung cancer stage I Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07720167 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07720167 is a hot trial to watch
Non-small cell lung cancer stage I is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07720167 is notable because it evaluates Albumin-Bound Paclitaxel in a Phase 2 design sponsored by The Medical University of South Carolina. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07720167 |
| Official title | Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Albumin-Bound Paclitaxel |
| Sponsor | The Medical University of South Carolina |
| Geography | United States |
| Enrollment | [object Object] |
| Primary endpoint | Frequency and percentage of patients with a pathologic complete response (pCR) rate |
| Endpoint time frame | 5.5 years |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
The study will investigate the role of cemiplimab in combination with platinum doublet chemotherapy in stage I resectable non-small cell lung cancer (NSCLC). Sub-4cm NSCLC tumors are highly lethal malignancies, yet no therapies are used in these patients to improve chances of survival with surgery alone. Here will be examined the ability of 3 cycles of cemiplimab-chemotherapy to induce pathologic complete responses to treatment.
Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment. Planned enrollment of [object Object] participants across United States shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Frequency and percentage of patients with a pathologic complete response (pCR) rate (5.5 years) — defined as the rate of ypT0N0 stage disease based on AJCC and UICC staging systems
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Albumin-Bound Paclitaxel is indexed as Chemical drugs, with target Tubulin, mechanism Tubulin inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: The Medical University of South Carolina is resolved to a normalized organization record in CHARLESTON COUNTY, United States. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07720167 provides a focused lens on Non-small cell lung cancer stage I development. Its value will be determined by whether Albumin-Bound Paclitaxel can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
